前列腺切除术
医学
激素疗法
前列腺癌
新辅助治疗
雄激素剥夺疗法
肿瘤科
阶段(地层学)
泌尿科
疾病
激素
局限性疾病
内科学
前列腺
激素疗法
癌症
乳腺癌
古生物学
生物
作者
Alessandro Tafuri,Maria Angela Cerruto,Alessandro Antonelli
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2020-12-31
卷期号:22 (1): 68-76
被引量:7
标识
DOI:10.2174/1389450121666200621194409
摘要
Prostate cancer (PCa) is a hormone dependent disease including several different patterns from indolent and clinically meaningless to aggressive and lethal disease. Among non-metastatic PCa, high-risk disease represents a therapeutically challenge, given the unfavorable oncological outcomes after exclusive local therapy. Deprivation therapy in the neoadjuvant setting is not recommended prior to radical prostatectomy since it did not provide any survival advantage, although reducing tumor volume, surgical margins rate, local and nodal stage. However, in the few recent years, new hormonal treatments for metastatic PCa emerged, and showed a relevant increase of overall survival with respect to classical androgen deprivation therapy (ADT). Thus, neo-adjuvant regimens of ADT based on these novel molecules are now under investigation and the results of ongoing clinical trials are expected in order to provide a definitive answer on the real role of neoadjuvant hormonal therapy in the treatment of high-risk localized prostate cancer. In this narrative review, we underline the role of neoadjuvant therapy before radical prostatectomy in high-risk PCa patients considering the impact of the new available hormonal agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI